• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚胺培南/西司他丁颗粒栓子特性的体外研究

In vitro study of the embolic characteristics of imipenem/cilastatin particles.

作者信息

Nakamura Hiroki, Yamamoto Akira, Fukunaga Takeshi, Watanabe Hiroyuki, Ito Kosuke, Higaki Atushi, Kanki Akihiko, Fukukura Yoshihiko, Tamada Tsutomu

机构信息

Departments of Radiology, Kawasaki Medical School, 577 , Matsushima, Kurashiki City, Okayama, Japan.

出版信息

CVIR Endovasc. 2024 Mar 11;7(1):27. doi: 10.1186/s42155-024-00441-x.

DOI:10.1186/s42155-024-00441-x
PMID:38466503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10928051/
Abstract

BACKGROUND

Imipenem/cilastatin (IPM/CS) has long been administered intravenously as a carbapenem antibiotic. However, since this agent is poorly soluble in liquid, occasional reports have described its use as a short-acting, temporary embolic agent. The purpose of this study was to elucidate the characteristics of IPM/CS particles, which are thought to have pain-relieving effects against osteoarthritis-related pain, as an embolic agent.

METHODS

Three aspects of IPM/CS as an embolic agent were evaluated in vitro: particle size; particle shape; and change in particle size over time. For particle size, the long diameter was measured.

RESULTS

Mean particle size (n=244) was 29.2±12.0 µm (range, 1-60 µm). Shape (n=109) was round in 18.35%, elliptical in 11.93%, and polygonal in 69.72%, showing that most particles were polygonal. In observations of changes in particle size over time (n=9), particles had decreased to 75% of their original size at 82±10.7 min, 50% at 89.3±9.14 min, 25% at 91.3±8.74 min, complete dissolved at 91.8±9.02 min. A rapid shrinkage in diameter was seen in the final period.

CONCLUSIONS

IPM/CS particles are ultrafine and the majority display a polygonal shape. This substance shows ultra-short embolic activity. This study revealed the characteristics of a substance that demonstrates an embolic effect not found in existing embolic materials.

摘要

背景

亚胺培南/西司他丁(IPM/CS)长期以来一直作为碳青霉烯类抗生素进行静脉给药。然而,由于该药物在液体中溶解度较差,偶尔有报道称其可作为短效临时栓塞剂使用。本研究的目的是阐明IPM/CS颗粒作为栓塞剂对骨关节炎相关疼痛具有止痛作用的特性。

方法

在体外评估IPM/CS作为栓塞剂的三个方面:粒径、颗粒形状以及粒径随时间的变化。对于粒径,测量其长径。

结果

平均粒径(n = 244)为29.2±12.0 µm(范围为1 - 60 µm)。颗粒形状(n = 109):圆形占18.35%,椭圆形占11.93%,多边形占69.72%,表明大多数颗粒为多边形。在观察粒径随时间的变化(n = 9)时,颗粒在82±10.7分钟时减小至原始大小的75%,在89.3±9.14分钟时减小至50%,在91.3±8.74分钟时减小至25%,在91.8±9.02分钟时完全溶解。在最后阶段观察到直径迅速缩小。

结论

IPM/CS颗粒极细,大多数呈多边形。该物质显示出超短的栓塞活性。本研究揭示了一种具有栓塞作用的物质的特性,这种特性在现有的栓塞材料中未发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/425dfa777df7/42155_2024_441_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/a7704663e95d/42155_2024_441_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/2a0b39a76396/42155_2024_441_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/5ca7cd2bd34c/42155_2024_441_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/c6841fcf5a56/42155_2024_441_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/ba9c58db85fe/42155_2024_441_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/425dfa777df7/42155_2024_441_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/a7704663e95d/42155_2024_441_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/2a0b39a76396/42155_2024_441_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/5ca7cd2bd34c/42155_2024_441_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/c6841fcf5a56/42155_2024_441_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/ba9c58db85fe/42155_2024_441_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536a/10928051/425dfa777df7/42155_2024_441_Fig6_HTML.jpg

相似文献

1
In vitro study of the embolic characteristics of imipenem/cilastatin particles.亚胺培南/西司他丁颗粒栓子特性的体外研究
CVIR Endovasc. 2024 Mar 11;7(1):27. doi: 10.1186/s42155-024-00441-x.
2
Embolic Characteristics of Imipenem-Cilastatin Particles in Vitro and in Vivo: Implications for Transarterial Embolization in Joint Arthropathies.亚胺培南-西司他丁颗粒在体外和体内的栓塞特性:对关节病经动脉栓塞的意义
J Vasc Interv Radiol. 2021 Jul;32(7):1031-1039.e2. doi: 10.1016/j.jvir.2021.02.006. Epub 2021 Feb 16.
3
Imipenem/cilastatin sodium (IPM/CS) as an embolic agent for transcatheter arterial embolisation: a preliminary clinical study of gastrointestinal bleeding from neoplasms.亚胺培南/西司他丁钠(IPM/CS)作为经导管动脉栓塞术的栓塞剂:肿瘤所致胃肠道出血的初步临床研究
Springerplus. 2013 Jul 26;2:344. doi: 10.1186/2193-1801-2-344. eCollection 2013.
4
[Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group].亚胺培南/西司他丁钠在新生儿和早产儿中的药代动力学及临床评价。围产期联合研究组对亚胺培南/西司他丁钠的一项研究
Jpn J Antibiot. 1989 Apr;42(4):953-72.
5
[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants].亚胺培南/西司他丁钠在新生儿和早产儿中的药代动力学及临床评价
Jpn J Antibiot. 1989 May;42(5):1102-24.
6
[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates].亚胺培南/西司他丁钠在新生儿中的药代动力学及临床疗效
Jpn J Antibiot. 1988 Nov;41(11):1704-14.
7
[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in the perinatal period. A study of imipenem/cilastatin sodium in the perinatal co-research group].亚胺培南/西司他丁钠围生期的药代动力学及临床研究。围生期联合研究组关于亚胺培南/西司他丁钠的一项研究
Jpn J Antibiot. 1988 Nov;41(11):1731-41.
8
Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study.使用亚胺培南/西司他丁进行经导管动脉栓塞治疗急性下消化道出血:一项单中心回顾性研究。
CVIR Endovasc. 2023 Mar 10;6(1):12. doi: 10.1186/s42155-023-00359-w.
9
Transcatheter arterial embolization of abnormal neovessels in a swine model of knee arthritis.经导管动脉栓塞膝关节关节炎猪模型中的异常新生血管。
Knee. 2022 Jun;36:20-26. doi: 10.1016/j.knee.2022.03.013. Epub 2022 Apr 11.
10
[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery].亚胺培南/西司他丁钠在小儿外科的药代动力学及临床评价
Jpn J Antibiot. 1988 Nov;41(11):1721-30.

引用本文的文献

1
Tophaceous gout of the knee: successful treatment with transarterial microembolization.膝部痛风石性痛风:经动脉微栓塞术治疗成功
Skeletal Radiol. 2025 Aug 27. doi: 10.1007/s00256-025-05021-1.
2
Transcatheter Arterial Embolization as a Treatment for Chronic Pain due to Osteoarthritis.经导管动脉栓塞术治疗骨关节炎所致慢性疼痛
Cardiovasc Intervent Radiol. 2025 May;48(5):687-693. doi: 10.1007/s00270-025-04008-8. Epub 2025 Mar 24.

本文引用的文献

1
Commentary on: A Retrospective Comparison of the Efficacy of Embolization with Imipenem/Cilastatin and Microspheres in the Management of Chronic Shoulder Pain.
Cardiovasc Intervent Radiol. 2023 Jun;46(6):758-759. doi: 10.1007/s00270-023-03429-7. Epub 2023 Apr 27.
2
A Retrospective Comparison of the Efficacy of Embolization with Imipenem/Cilastatin and Microspheres in the Management of Chronic Shoulder Pain.慢性肩痛管理中亚胺培南/西司他丁与微球栓塞疗效的回顾性比较。
Cardiovasc Intervent Radiol. 2023 Jun;46(6):748-757. doi: 10.1007/s00270-023-03385-2. Epub 2023 Feb 24.
3
Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents.腱病大动物模型中新血管栓塞的可行性:各种栓塞剂的安全性和有效性
J Pers Med. 2022 Sep 18;12(9):1530. doi: 10.3390/jpm12091530.
4
Characteristics of Imipenem/Cilastatin: Considerations for Musculoskeletal Embolotherapy.亚胺培南/西司他丁的特性:肌肉骨骼栓塞治疗的考量因素
J Vasc Interv Radiol. 2021 Jul;32(7):1040-1043.e1. doi: 10.1016/j.jvir.2021.04.006. Epub 2021 Jun 10.
5
Embolic Characteristics of Imipenem-Cilastatin Particles in Vitro and in Vivo: Implications for Transarterial Embolization in Joint Arthropathies.亚胺培南-西司他丁颗粒在体外和体内的栓塞特性:对关节病经动脉栓塞的意义
J Vasc Interv Radiol. 2021 Jul;32(7):1031-1039.e2. doi: 10.1016/j.jvir.2021.02.006. Epub 2021 Feb 16.
6
Genicular Artery Embolization for Osteoarthritis Related Knee Pain: A Systematic Review and Qualitative Analysis of Clinical Outcomes.关节内动脉栓塞治疗膝关节骨关节炎相关疼痛:临床结局的系统评价和定性分析。
Cardiovasc Intervent Radiol. 2021 Jan;44(1):1-9. doi: 10.1007/s00270-020-02687-z. Epub 2020 Nov 1.
7
"Point of no return" in unilateral renal ischemia reperfusion injury in mice.在单侧肾缺血再灌注损伤的小鼠模型中“不可逆转点”。
J Biomed Sci. 2020 Feb 14;27(1):34. doi: 10.1186/s12929-020-0623-9.
8
Early Results of Transcatheter Arterial Embolization for Relief of Chronic Shoulder or Elbow Pain Associated with Tendinopathy Refractory to Conservative Treatment.经导管动脉栓塞治疗对慢性肩或肘疼痛伴保守治疗无效的肌腱病的早期疗效。
J Vasc Interv Radiol. 2018 Apr;29(4):510-517. doi: 10.1016/j.jvir.2017.11.013. Epub 2018 Feb 22.
9
Midterm Clinical Outcomes and MR Imaging Changes after Transcatheter Arterial Embolization as a Treatment for Mild to Moderate Radiographic Knee Osteoarthritis Resistant to Conservative Treatment.经导管动脉栓塞术治疗保守治疗无效的轻至中度影像学膝关节骨关节炎的中期临床疗效及磁共振成像变化
J Vasc Interv Radiol. 2017 Jul;28(7):995-1002. doi: 10.1016/j.jvir.2017.02.033. Epub 2017 Mar 30.
10
Clinical Outcomes of Transcatheter Arterial Embolization for Adhesive Capsulitis Resistant to Conservative Treatment.经导管动脉栓塞术治疗保守治疗无效的肩周炎的临床疗效
J Vasc Interv Radiol. 2017 Feb;28(2):161-167.e1. doi: 10.1016/j.jvir.2016.09.028. Epub 2016 Dec 19.